Systemic safety of bevacizumab versus ranibizumab for neovascular age-related macular degeneration

Lorenzo Moja, Ersilia Lucenteforte, Koren H. Kwag, Vittorio Bertele, Annalisa Campomori, Usha Chakravarthy, Roberto D'Amico, Kay Dickersin, Laurent Kodjikian, Kristina Lindsley, Yoon Loke, Maureen Maguire, Daniel F. Martin, Alessandro Mugelli, Bernd Mühlbauer, Isabel Püntmann, Barnaby Reeves, Chris Rogers, Christine Schmucker, Manju L. SubramanianGianni Virgili

Research output: Contribution to journalReview article

Abstract

This is the protocol for a review and there is no abstract. The objectives are as follows: To assess the systemic safety of intravitreal bevacizumab compared with intravitreal ranibizumab in people with neovascular AMD.

Original languageEnglish (US)
Article numberCD011230
JournalCochrane Database of Systematic Reviews
Volume2014
Issue number7
DOIs
StatePublished - Jul 24 2014

ASJC Scopus subject areas

  • Pharmacology (medical)

Fingerprint Dive into the research topics of 'Systemic safety of bevacizumab versus ranibizumab for neovascular age-related macular degeneration'. Together they form a unique fingerprint.

  • Cite this

    Moja, L., Lucenteforte, E., Kwag, K. H., Bertele, V., Campomori, A., Chakravarthy, U., D'Amico, R., Dickersin, K., Kodjikian, L., Lindsley, K., Loke, Y., Maguire, M., Martin, D. F., Mugelli, A., Mühlbauer, B., Püntmann, I., Reeves, B., Rogers, C., Schmucker, C., ... Virgili, G. (2014). Systemic safety of bevacizumab versus ranibizumab for neovascular age-related macular degeneration. Cochrane Database of Systematic Reviews, 2014(7), [CD011230]. https://doi.org/10.1002/14651858.CD011230